Role of Perinatal Inflammation in Cerebral Palsy

Pediatric Neurology

Volumn 40, Issue 3, 2009, Pages 168-174

  Girard, Sylvie ^a   Kadhim, Hazim ^b   Roy, Mélanie ^a   Lavoie, Karine ^a   Brochu, Marie Elsa ^a   Larouche, Annie ^a   Sébire, Guillaume ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BRAIN DAMAGE; BRAIN HYPOXIA; BRAIN INJURY; CEREBRAL PALSY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTRAUTERINE INFECTION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PERINATAL PERIOD; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CEREBRAL PALSY; CYTOKINES; FETUS; HUMANS; INFANT, NEWBORN; INFLAMMATION;

EID: 59749087031     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.09.016     Document Type: Article

References (79)

1. Nelson K.B. Can we prevent cerebral palsy?. N Engl J Med 349 (2003) 1765-1769
2. Volpe J.J. Hypoxic-ischemic encephalopathy. Neurology of the newborn. 4th ed. (2001), WB Saunders, Philadelphia 296-330
3. Kadhim H., Evrard P., Kahn A., De Prez C., Bonnier C., and Sébire G. Insights into etiopathogenic mechanisms involved in perinatal cerebral injury: implications for neuroprotection. In: Fong H.D. (Ed). Focus on cerebral palsy research (2005), Nova Biomedical Books, New York 1-27
4. Kadhim H., Sébire G., Kahn A., Evrard P., and Dan B. Causal mechanisms underlying periventricular leukomalacia and cerebral palsy. Curr Pediatr Rev 1 (2005) 1-6
5. Kuban K.C.K., and Leviton A. Cerebral palsy. N Engl J Med 330 (1994) 188-195
6. Nelson K.B., and Grether J.K. Potentially asphyxiating conditions and spastic cerebral palsy in infants of normal birth weight. Am J Obstet Gynecol 179 (1998) 507-513
7. Hagberg B., Hagberg G., Olow I., and von Wendt L. The changing panorama of cerebral palsy in Sweden: VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr 85 (1996) 954-960
8. Cummins S.K., Nelson K.B., Grether J.K., and Velie E.M. Cerebral palsy in four northern California counties, births 1983 through 1985. J Pediatr 123 (1993) 230-237
9. Robertson C.M., Svenson L.W., and Joffres M.R. Prevalence of cerebral palsy in Alberta. Can J Neurol Sci 25 (1998) 117-122
10. Winter S., Autry A., Boyle C., and Yeargin-Allsopp M. Trends in the prevalence of cerebral palsy in a population-based study. Pediatrics 110 (2002) 1220-1225
11. Topp M., Uldall P., and Langhoff-Roos J. Trend in cerebral palsy birth prevalence in eastern Denmark: birth-year period 1979-86. Paediatr Perinat Epidemiol 11 (1997) 451-460
12. Wilson-Costello D., Friedman H., Minich N., Fanaroff A.A., and Hack M. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 11 (2005) 997-1003
13. Illingworth R.S. A paediatrician asks-Why is it called birth injury?. Br J Obstet Gynaecol 92 (1985) 122-130
14. Blair E., and Stanley F.J. Intrapartum asphyxia: a rare cause of cerebral palsy [Erratum in: J Pediatr 1988;113:420]. J Pediatr 112 (1988) 515-519
15. Freeman J.M., and Nelson K.B. Intrapartum asphyxia and cerebral palsy. Pediatrics 82 (1988) 240-249
16. Bedrick A.D. Perinatal asphyxia and cerebral palsy: fact, fiction, or legal prediction?. Am J Dis Child 143 (1989) 1139-1140
17. Zupan V., Gonzalez P., Lacaze-Masmonteil T., et al. Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol 38 (1996) 1061-1067
18. Grether J.K., and Nelson K.B. Maternal infection and cerebral palsy in infants of normal birth weight [Erratum in: JAMA 1998 Jan 14;279:118]. JAMA 278 (1997) 207-211
19. Yoon B.H., Park C.W., and Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. BJOG 110 (2003) 124-127
20. Murphy D.J., Sellers S., MacKenzie I.Z., Yudkin P.L., and Johnson A.M. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 346 (1995) 1449-1454
21. Perlman J.M., Risser R., and Broyles R.S. Bilateral cystic periventricular leukomalacia in the premature infant: associated risk factors. Pediatrics 97 (1996) 822-827
22. Bracci R., and Buonocore G. Chorioamnionitis: a risk factor for fetal and neonatal morbidity. Biol Neonate 83 (2003) 85-96
23. Wu Y.W., Escobar G.J., Grether J.K., Croen L.A., Greene J.D., and Newman T.B. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA 290 (2003) 2677-2684
24. Stoll B.J., Gordon T., Korones S.B., et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 129 (1996) 72-80
25. Nelson K.B., and Willoughby R.E. Infection, inflammation and the risk of cerebral palsy. Curr Opin Neurol 13 (2000) 133-139
26. Wu Y.W., and Colford Jr. J.M. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA 284 (2000) 1417-1424
27. Nguyen M.D., Julien J.P., and Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration. Nature Rev Neurosci 3 (2002) 216-227
28. Vitkovic L., Bockaert J., and Jacque C. Inflammatory" cytokines: neuromodulators in normal brain?. J Neurochem 74 (2000) 457-471
29. Mehler M.F., and Kessler J.A. Cytokines in brain development and function. Adv Protein Chem 52 (1998) 223-251
30. Gosselin D., and Rivest S. Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. Brain Behav Immun 21 (2007) 281-289
31. Dammann O., and Leviton A. Brain damage in preterm newborns: biological response modification as a strategy to reduce disabilities. J Pediatr 136 (2000) 433-438
32. Nelson K.B., Dambrosia J.M., Grether J.K., and Phillips T.M. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 44 (1998) 665-675
33. Yoon B.H., Jun J.K., Romero R., et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1β, and tumor necrosis factor-α), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 177 (1997) 19-26
34. Baud O., Emilie D., Pelletier E., et al. Amniotic fluid concentrations of interleukin-1β, interleukin-6 and TNF-α in chorioamnionitis before 32 weeks of gestation: histological associations and neonatal outcome. Br J Obstet Gynaecol 106 (1999) 72-77
35. Nelson K.B., Grether J.K., Dambrosia J.M., et al. Neonatal cytokines and cerebral palsy in very preterm infants. Pediatr Res 53 (2003) 600-607
36. Kadhim H., Tabarki B., Verellen G., De Prez C., Rona A.M., and Sébire G. Inflammatory cytokines in the pathogenesis of periventricular leukomalacia. Neurology 56 (2001) 1278-1284
37. Kadhim H., Tabarki B., De Prez, and Sébire G. Cytokine immunoreactivity in cortical and subcortical neurons in periventricular leukomalacia: are cytokines implicated in neuronal dysfunction in cerebral palsy?. Acta Neuropathol 105 (2003) 209-216
38. Kadhim H., and Sébire G. Immune mechanisms in the pathogenesis of cerebral palsy: implication of proinflammatory cytokines and T lymphocytes. Eur J Paediatr Neurol 6 (2002) 139-142
39. Yoon B.H., Romero R., Kim C.J., et al. High expression of tumor necrosis factor-α and interleukin-6 in periventricular leukomalacia. Am J Obstet Gynecol 177 (1997) 406-411
40. Deguchi K., Oguchi K., and Takashima S. Characteristic neuropathology of leukomalacia in extremely low birth weight infants. Pediatr Neurol 16 (1997) 296-300
41. Sébire G., Emilie D., Wallon C., et al. In vitro production of IL-6, IL-1 beta, and tumor necrosis factor-alpha by human embryonic microglial and neural cells. J Immunol 150 (1993) 1517-1523
42. Selmaj K.W., and Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23 (1988) 339-346
43. Selmaj K., Raine C.S., Farooq M., Norton W.T., and Brosnan C.F. Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol 147 (1991) 1522-1529
44. Cammer W., and Zhang H. Maturation of oligodendrocytes is more sensitive to TNF alpha than is survival of precursors and immature oligodendrocytes. J Immunol 97 (1999) 37-42
45. Cammer W. Effects of TNFα on immature and mature oligodendrocytes and their progenitors in vitro. Brain Res 864 (2000) 213-219
46. Sherwin C., and Fern R. Acute lipopolysaccharide-mediated injury in neonatal white matter glia: role of TNF-α, IL-1β, and calcium. J Immunol 175 (2005) 155-161
47. Cai Z., Lin S., Pang Y., and Rhodes P.G. Brain injury induced by intracerebral injection of interleukin-1beta and tumor necrosis factor-alpha in the neonatal rat. Pediatr Res 56 (2004) 377-384
48. Dommergues M.A., Patkai J., Renauld J.C., Evrard P., and Gressens P. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann Neurol 47 (2000) 54-63
49. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., and Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α. Proc Natl Acad Sci U S A 92 (1995) 11294-11298
50. Taupin V., Renno T., Bourbonnière L., Peterson A.C., Rodriguez M., and Owens T. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-α in the central nervous system. Eur J Immunol 27 (1997) 905-913
51. Körner H., Riminton D.S., Strickland D.H., Lemckert F.A., Pollard J.D., and Sedgwick J.D. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 186 (1997) 1585-1590
52. Eugster H.P., Frei K., Bachmann R., Bluethmann H., Lassmann H., and Fontana A. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 29 (1999) 626-632
53. Bruce A.J., Boling W., Kindy M.S., et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 2 (1996) 788-794
54. Suzuki N., Suzuki S., Duncan G.S., et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416 (2002) 750-756
55. Huang F.P., Wang Z.Q., Wu D.C., Schielke G.P., Sun Y., and Yang G.Y. Early NFκB activation is inhibited during focal cerebral ischemia in interleukin-1β-converting enzyme deficient mice. J Neurosci Res 73 (2003) 698-707
56. Basu A., Lazovic J., Krady J.K., et al. Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J Cereb Blood Flow Metab 25 (2005) 17-29
57. Pringle A.K., Niyadurupola N., Johns P., Anthony D.C., and Iannotti F. Interleukin-1β exacerbates hypoxia-induced neuronal damage, but attenuates toxicity produced by simulated ischaemia and excitotoxicity in rat organotypic hippocampal slice cultures. Neurosci Lett 305 (2001) 29-32
58. Parnet P., Pousset F., and Laye S. NFκB activation in mouse pituitary: comparison of response to interleukin-1β and lipopolysaccharide. J Neuroendocrinol 15 (2003) 304-314
59. Hu X., Nesic-Taylor O., Qiu J., et al. Activation of nuclear factor-κB signaling pathway by interleukin-1 after hypoxia/ischemia in neonatal rat hippocampus and cortex. J Neurochem 93 (2005) 26-37
60. Pinteaux E., Rothwell N.J., and Boutin H. Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia 53 (2006) 551-556
61. Patel H.C., Boutin H., and Allan S.M. Interleukin-1 in the brain; mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci 992 (2003) 39-47
62. Scherbel U., Raghupathi R., Nakamura M., et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A 96 (1999) 8721-8726
63. Bona E., Andersson A.L., Blomgren K., et al. Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats. Pediatr Res 45 (1999) 500-509
64. Akassoglou K., Douni E., Bauer J., Lassmann H., Kollias G., and Probert L. Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci U S A 100 (2003) 709-714
65. Kadhim H., Khalifa M., Deltenre P., Casimir G., and Sébire G. Molecular mechanisms of cell death in periventricular leukomalacia. Neurology 67 (2006) 293-299
66. Duggan P.J., Maalouf E.F., Watts T.L., et al. Intrauterine T-cell activation and increased proinflammatory cytokine concentrations in preterm infants with cerebral lesions. Lancet 358 (2001) 1699-1700
67. Haynes R.L., Folkerth R.D., Keefe R.J., et al. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol 62 (2003) 441-450
68. Cai Z., Pan Z.L., Pang Y., Evans O.B., and Rhodes P.G. Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration. Pediatr Res 47 (2000) 64-72
69. Elovitz M.A., Mrinalini C., and Sammel M.D. Elucidating the early signal transduction pathways leading to fetal brain injury in preterm birth. Pediatr Res 59 (2006) 50-55
70. Bell M.J., Hallenbeck J.M., and Gallo V. Determining the fetal inflammatory response in an experimental model of intrauterine inflammation in rats. Pediatr Res 56 (2004) 541-546
71. Rousset C.I., Chalon S., Cantagrel S., et al. Maternal exposure to LPS induces hypomyelination in the internal capsule and programmed cell death in the deep gray matter in newborn rats. Pediatr Res 59 (2006) 428-433
72. Coumans A.B., Middelanis J.S., Garnier Y., et al. Intracisternal application of endotoxin enhances the susceptibility to subsequent hypoxic-ischemic brain damage in neonatal rats. Pediatr Res 53 (2003) 770-775
73. Szaflarski J., Burtrum D., and Silverstein F.S. Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. Stroke 26 (1995) 1093-1100
74. Hagberg H., Gilland E., Bona E., et al. Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats. Pediatr Res 40 (1996) 603-609
75. Larouche A., Roy M., Kadhim H., Tsanaclis A.M., Fortin D., and Sébire G. Neuronal injuries induced by perinatal hypoxic-ischemic insults are potentiated by prenatal exposure to lipopolysaccharide: an animal model for perinatally acquired encephalopathy. Dev Neurosci 27 (2005) 134-142
76. Dalitz P., Harding R., Rees S.M., and Cock M.L. Prolonged reductions in placental blood flow and cerebral oxygen delivery in preterm fetal sheep exposed to endotoxin: possible factors in white matter injury after acute infection. J Soc Gynecol Investig 10 (2003) 283-290
77. Peebles D.M., Miller S., Newman J.P., Scott R., and Hanson M.A. The effect of systemic administration of lipopolysaccharide on cerebral haemodynamics and oxygenation in the 0.65 gestation ovine fetus in utero. BJOG 110 (2003) 735-743
78. Girard S., Kadhim H., Larouche A., Roy M., Gobeil F., and Sébire G. Pro-inflammatory disequilibrium of the IL-1β/IL-1ra ratio in an experimental model of perinatal brain damages induced by lipopolysaccharide and hypoxia-ischemia. Cytokine 43 (2008) 54-62
79. Lenercept Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53 (1999) 457-465